Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Frequency Therapeutics, Inc. (FREQ)
Sector: Healthcare; Industry: Biotechnology

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-17 McCubbin Quentin Chief Manufacturing Officer Buy 10,000 $8.85 $88,500 No
2021-03-01 Lucchino David L. President and CEO Sell 9,416 $50.43 $474,836 Yes
2021-02-08 Lucchino David L. President and CEO Sell 16,554 $55.00 $910,470 Yes
2021-02-03 Lucchino David L. President and CEO Sell 11,036 $48.75 $538,005 Yes
2021-02-02 Lucchino David L. President and CEO Sell 5,518 $46.10 $254,360 Yes
2021-02-01 Lucchino David L. President and CEO Sell 33,102 $43.09 $1,426,370 Yes
2021-02-03 Loose Christopher R. Chief Scientific Officer Sell 10,000 $45.46 $454,576 No
2021-01-27 Lucchino David L. President and CEO Sell 9,196 $42.50 $390,830 Yes
2021-01-27 Loose Christopher R. Chief Scientific Officer Sell 8,000 $42.50 $340,000 No
2021-01-06 Lucchino David L. President and CEO Sell 27,586 $38.57 $1,063,917 Yes
2021-01-04 Lucchino David L. President and CEO Sell 34,104 $33.21 $1,132,740 Yes
2020-12-22 MARCUS JOEL S Director Sell 49,700 $34.25 $1,702,412 No
2020-12-17 Lucchino David L. President and CEO Sell 1,120 $42.64 $47,755 Yes
2020-12-17 Loose Christopher R. Chief Scientific Officer Sell 8,000 $40.63 $325,001 No
2020-12-16 Lucchino David L. President and CEO Sell 40,542 $37.84 $1,534,061 Yes
2020-12-16 Loose Christopher R. Chief Scientific Officer Sell 24,000 $37.07 $889,720 No
2020-12-09 Lucchino David L. President and CEO Sell 13,514 $32.93 $444,984 Yes
2020-12-08 Lucchino David L. President and CEO Sell 13,514 $30.83 $416,686 Yes
2020-12-01 Lucchino David L. President and CEO Sell 15,714 $27.93 $438,871 No
2020-11-09 Loose Christopher R. Chief Scientific Officer Sell 16,000 $23.50 $376,000 No
2020-11-02 Lucchino David L. President and CEO Sell 15,714 $20.81 $326,972 No
2020-10-13 Loose Christopher R. Chief Scientific Officer Sell 8,000 $22.00 $176,000 No
2020-10-08 Loose Christopher R. Chief Scientific Officer Sell 24,000 $20.19 $484,650 No
2020-10-05 Loose Christopher R. Chief Scientific Officer Sell 24,000 $18.70 $448,880 No
2020-10-01 Lucchino David L. President and CEO Sell 15,716 $19.13 $300,658 No
2020-09-23 Loose Christopher R. Chief Scientific Officer Sell 4,500 $21.13 $95,097 No
2020-09-09 Loose Christopher R. Chief Scientific Officer Sell 4,500 $18.97 $85,369 No
2020-09-01 Lucchino David L. President and CEO Sell 15,714 $18.55 $291,474 No
2020-08-19 Loose Christopher R. Chief Scientific Officer Sell 4,500 $22.97 $103,350 No
2020-08-05 Loose Christopher R. Chief Scientific Officer Sell 4,500 $21.21 $95,464 No

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.